How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,776 results for

Dry Mouth

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Clinical Evaluation of a Royal Jelly Supplementation for the Restoration of Dry Eye: A Prospective Randomized Double Blind Placebo Controlled Study and an Experimental Mouse Model. Full Text available with Trip Pro

Clinical Evaluation of a Royal Jelly Supplementation for the Restoration of Dry Eye: A Prospective Randomized Double Blind Placebo Controlled Study and an Experimental Mouse Model. Dry eye is a multifactorial disease characterized by ocular discomfort and visual impairment. Lacrimal gland function has been shown to decrease with aging, a known potent risk factor for dry eye. We have previously found that orally administrated royal jelly (RJ) restored tear secretion in a rat model of dry eye.We (...) examined the effects of RJ oral administration on dry eye in this prospective, randomized, double-blind, placebo-controlled study. Forty-three Japanese patients aged 20-60 years with subjective dry eye symptoms were randomized to an RJ group (1200 mg/tablet, six tablets daily) or a placebo group for 8 weeks. Keratoconjunctival epithelial damage, tear film break-up time, tear secretion volume, meibum grade, biochemical data, and subjective dry eye symptoms based on a questionnaire were investigated

2017 PloS one Controlled trial quality: predicted high

182. Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study. (Abstract)

Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study. To investigate whether oral, long-chain omega-3 (ω-3) essential fatty acid (EFA) supplementation, for 3 months, induces changes to the central corneal sub-basal nerve plexus in dry eye disease and whether nerve alterations correlate with clinical findings.This prospective, comparative study involved the final 12 participants enrolled in a randomised, double-masked, placebo-controlled clinical trial (...) of 60 participants with moderate dry eye disease. Participants received either placebo (olive oil 1500 mg/day; n = 4) or ω-3 EFA supplements (~1000 mg/day eicosapentaenoic acid + ~500 mg/day docosahexaenoic acid; n = 8) for 90 days. The main outcome measure was the mean change in central corneal sub-basal plexus nerve parameters between days one and 90, quantified using in vivo confocal microscopy. Secondary outcomes included mean change in tear osmolarity, corneal dendritic cell density and basal

2017 Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) Controlled trial quality: predicted high

183. A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma. (Abstract)

A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma. A novel multidose dry powder inhaler (MDPI) that is breath actuated, easy, and intuitive to use has been developed for administering fluticasone propionate (Fp) and Fp/salmeterol (FS).To assess the safety and efficacy of Fp MDPI versus Fp hydrofluoroalkane (HFA) and FS MDPI versus FS dry-powder inhaler (DPI).This phase III, 26-week, open-label (...) assessed by adverse events (AE) and pulmonary function and asthma symptoms, respectively.A total of 674 subjects were randomized. The AE incidence was similar across treatment groups (upper respiratory tract infections, sinusitis, and nasopharyngitis were most frequent). A higher percentage of subjects in the Fp HFA 440 μg and FS DPI 500/50 μg groups had oral candidiasis versus those who received Fp MDPI 200 μg or FS MDPI 200/12.5 μg, respectively. Serious AEs were similar between the treatments

2017 Allergy and Asthma Proceedings Controlled trial quality: uncertain

184. The role of systemic and topical fatty acids for dry eye treatment. (Abstract)

in n-3 EFAs and this ratio is typically much higher (approaching 17:1). The metabolism of EFAs generates four new families of local acting mediators: lipoxins, resolvins, protectins, and maresins. These molecules have anti-inflammatory and pro-resolution properties. We present a critical overview of animal model studies and human clinical trials that have shown that dietary modification and oral supplementation could be complementary therapeutic strategies for the treatment of dry eye. Furthermore (...) The role of systemic and topical fatty acids for dry eye treatment. Dry eye is a prevalent condition and one of the main reasons for patients to seek ophthalmic medical care. A low systemic level of omega fatty acids is a risk factor for dry eye disease (DED). There are two groups of essential fatty acids (EFAs): the omega-6 (n-6) family and the omega-3 (n-3) family. Humans evolved on a diet in which the n-6:n-3 ratio was approximately 1:1, however the current Western diet tends to be deficient

2017 Progress in Retinal and Eye Research

185. Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care

2016 Clinical Trials

186. A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pu

: Placebo DISKUS It is a placebo dry powder inhaler with one blister strip containing lactose monohydrate. Device: Placebo HANDIHALER Placebo capsules contain lactose monohydrate in the form of powder for oral inhalation, to be used with HANDIHALER device. Other: PQ1 Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses. Experimental: Sub-study (...) It is a placebo dry powder inhaler with one blister strip containing lactose monohydrate. Device: Placebo HANDIHALER Placebo capsules contain lactose monohydrate in the form of powder for oral inhalation, to be used with HANDIHALER device. Other: PQ2 Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions. Experimental: Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ2 In this sequence, subjects

2016 Clinical Trials

187. Chronic pain: oral ketamine

adverse effects of oral ketamine reported in Haines and Gaines (1999) included headache, light headedness, dizziness, tiredness and a 'nervous floating feeling' . Furuhashi-Yonaha et al. (2002) also reported headache as an adverse effect of oral ketamine, and Rabben et al. (1999) reported 'mental' adverse effects with oral ketamine. In a case series of oral ketamine given for 3 months (Cvrcek 2008), the most common adverse effects included drowsiness, dizziness, dry mouth and sedation. The summary (...) Chronic pain: oral ketamine Chronic pain: or Chronic pain: oral k al ketamine etamine Evidence summary Published: 25 February 2014 nice.org.uk/guidance/esuom27 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in February 2014. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Two small, short-term

2014 National Institute for Health and Clinical Excellence - Advice

188. A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI. (Abstract)

'). Safety assessments included adverse events (AEs). A total of 287 patients were randomized. A significantly (p < 0.001) larger proportion of patients preferred the ELLIPTA DPI over DISKUS DPI for each of the tested attributes and overall, and preferred once-daily over twice-daily dosing. AEs were reported for 36 patients (13%); one (dry mouth) was considered to be related to the placebo-containing DISKUS DPI. Three patients had five non-fatal serious AEs, none were deemed inhaler-related. This study (...) A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI. Patients' preference is an important factor in selecting an inhaler treatment for COPD. The DISKUS® dry powder inhaler (DPI), which has been available to deliver several COPD medications for a decade, and the ELLIPTA® DPI, developed for the delivery of newer once-daily medications for patients with COPD, were studied in terms of patient preference and inhaler

2015 COPD Controlled trial quality: uncertain

189. The Effect of Preoperative Oral Carbohydrate Solution Intake on Patient Comfort: A Randomized Controlled Study. (Abstract)

in the glucose and fasting groups than the CHD group (P < .01). In the postoperative period, the fasting group experienced more vomiting and pain compared with the CHD group (P < .05). A significant difference was found between the groups in terms of diastolic blood pressure and pulse rate in the preoperative and intraoperative periods (P < .05).The CHD treatment before thyroidectomy increases patient comfort by reducing preoperative discomfort (such as hunger, thirst, dry mouth, fatigue and headache (...) The Effect of Preoperative Oral Carbohydrate Solution Intake on Patient Comfort: A Randomized Controlled Study. The study was conducted to investigate the effect of preoperative oral carbohydrate loading on the preoperative discomforts and postoperative complications of patients undergoing elective thyroidectomy.A randomized controlled clinical trial.Ninety patients scheduled for thyroidectomy were divided into three groups: (1) those receiving a carbohydrate-rich drink (CHD), (2) those

2018 Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses Controlled trial quality: uncertain

190. Espranor (buprenorphine oral lyophilisate) 2mg and 8mg

for administration, the dissolution rate will be less than the solid dose form. 3 Administration issues The oral lyophilisate should be removed from the blister pack with dry fingers – any contact with moisture will result in disintegration of the wafer. The oral lyophilisate must be placed whole on the tongue until dispersed. This is different to current buprenorphine tablets which are placed under the tongue. Healthcare professionals need to be clear about this to advise patients and avoid administration (...) errors. Placing Espranor on the tongue makes supervision of dosing easier as it instantly begins to disintegrate making removal from the mouth for the purposes of diversion impossible. If the oral lyophilisate or saliva containing buprenorphine is swallowed, the buprenorphine will be metabolised, excreted and have minimal effect. [2] Swallowing should be avoided for 2 minutes. Food and drink should not be consumed for 5 minutes after administration. [2] This may require observation of people having

2017 Specialist Pharmacy Services

191. Foot-and-Mouth Disease Virus: Stability of Neutralizing Antibody After Freeze-drying and Air-drying Full Text available with Trip Pro

Foot-and-Mouth Disease Virus: Stability of Neutralizing Antibody After Freeze-drying and Air-drying It is possible to stabilize foot-and-mouth disease antiserum by either freeze-drying in bottles or air-drying on paper for periods of 7 months.

1969 Applied microbiology

192. Factors affecting institutionalized older peoples’ self-perceived dry mouth Full Text available with Trip Pro

results showed that the type of long-term care (LTC) facility, regular oral examinations, wearing dentures, and the ability to chew sticky foods affected self-perceived dry mouth. This study determined an association between the type of LTC facility where the participants lived and self-perceived dry mouth.The results indicated the importance of providing oral care in order to improve and prevent dry mouth among institutionalized older people living in SCWIs who do not undergo regular oral (...) Factors affecting institutionalized older peoples’ self-perceived dry mouth The purpose of this study was to determine the factors affecting institutionalized older peoples' self-perceived dry mouth.This cross-sectional study was conducted on elderly residents at 22 long-term care facilities. A total of 165 questionnaires were returned from 13 senior citizen welfare institutions (SCWIs) and nine nursing homes. Multiple logistic regression analysis was used to analyze the data obtained.The

2014 Quality of Life Research

193. Limited evidence for non-pharmacological interventions for the relief of dry mouth. (Abstract)

Limited evidence for non-pharmacological interventions for the relief of dry mouth. The Cochrane Oral Health Group's Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, AMED, CINAHL and CANCERLIT databases were searched. The metaRegister of Controlled Clinical Trials and ClinicalTrials.gov were also searched to identify ongoing and completed trials. Reference lists of included studies and relevant reviews were also searched. There were no restrictions (...) on the language of publication or publication status.Randomised controlled trials of non-pharmacological treatments for patients with dry mouth at baseline.Study assessment and data extraction were carried out independently by at least two reviewers. Mean difference (MD) and standardised mean differences (SMD) together with 95% CIs were calculated where appropriate.Nine studies (366 participants) were included in this review, eight were assessed at high risk of bias and one at unclear risk of bias. Five small

2014 Evidence Based Dentistry

194. Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome

Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02092207 Recruitment Status : Completed First Posted : March

2014 Clinical Trials

195. Managing the care of patients with Sjögren syndrome and dry mouth: Comorbidities, medication use and dental care considerations. (Abstract)

Managing the care of patients with Sjögren syndrome and dry mouth: Comorbidities, medication use and dental care considerations. As North Americans live longer, have more chronic conditions and take more medications, adverse oral events are likely to increase and aggravate the symptoms of Sjögren syndrome (SS).A total of 151 adults who self-reported having SS and who had a mean (standard deviation [SD]) age of 65.8 (11.5) years completed a survey that included questions about basic demographic (...) information, current medical conditions, medications used (prescription and over the counter [OTC]) and the use of oral products to manage SS symptoms. Owing to the self-reporting process in our survey, the term "SS" in our study population represented a mixture of people with SS and people with dry mouth symptoms.The mean (SD) number of daily medications recorded as prescription, OTC and oral care products were 4.9 (3.5), 4.5 (2.8) and 4.6 (1.4), respectively. Participants with four or more comorbid

2014 Journal of the American Dental Association

196. A randomized clinical trial of an intervention to relieve thirst and dry mouth in intensive care unit patients. Full Text available with Trip Pro

cognitively intact patients reporting thirst intensity (TI) and/or thirst distress (TD) scores ≥3 on 0-10 numeric rating scales (NRS) were randomized to intervention or usual care groups. A research team nurse (RTN#1) obtained patients' pre-procedure TI and TD scores and reports of dry mouth. She then administered a thirst bundle to the intervention group: oral swab wipes, sterile ice-cold water sprays, and a lip moisturizer, or observed patients in the usual care group. RTN#2, blinded to group assignment (...) A randomized clinical trial of an intervention to relieve thirst and dry mouth in intensive care unit patients. To test an intervention bundle for thirst intensity, thirst distress, and dry mouth, which are among the most pervasive, intense, distressful, unrecognized, and undertreated symptoms in ICU patients, but for which data-based interventions are lacking.This was a single-blinded randomized clinical trial in three ICUs in a tertiary medical center in urban California. A total of 252

2014 Intensive Care Medicine Controlled trial quality: uncertain

197. [Prognosis and treatment of dry mouth. Systematic review.] Full Text available with Trip Pro

[Prognosis and treatment of dry mouth. Systematic review.] There are no clearly established protocols for the treatment of dry mouth. The aim of this paper is a systematic review of the literature of the past 10 years using the words « dry mouth », « prognosis », « treatment » and « dentistry ». The initial search found 1,450 entries and within the restriction « clinical trials OR randomized controlled trial OR systemic reviews » it has been reduced to 522, which 145 were meta-analysis

2014 Medicina clinica

198. Hyperhidrosis: oral glycopyrronium bromide

. Summary There is weak evidence from case series that oral glycopyrronium bromide tablets reduce sweating in people with hyperhidrosis. The most commonly reported adverse effects are antimuscarinic, particularly dry mouth. There is no randomised controlled trial evidence of the use of oral glycopyrronium bromide for hyperhidrosis. Regulatory status Regulatory status: unlicensed © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights (...) be an early symptom of incomplete intestinal obstruction. P Patient factors atient factors Glycopyrronium bromide tablets and oral solution or suspension are imported or prepared by 'specials' manufacturers. Dosage varies, ranging from 1 mg to a maximum 8 mg (in divided doses) daily in case series. Across case series 29–79% of participants experienced adverse effects, most frequently dry mouth (affecting 16–63%). In 3 case series, 26%, 20% and 3% of participants withdrew because of adverse effects. In 2

2013 National Institute for Health and Clinical Excellence - Advice

199. Hypersalivation: oral glycopyrronium bromide

dry mouth. There is no evidence of its long-term efficacy or safety in treating hypersalivation. Regulatory status: Regulatory status: unlicensed. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 35Effectiv Effectiveness eness Oral glycopyrronium bromide significantly improved drooling in children and young people with neurological conditions compared with placebo (2 randomised controlled trials [RCTs], 8 (...) ) therapy and with concomitant oral potassium chloride. The most commonly reported adverse effects listed are dry mouth, vomiting, constipation, flushing and nasal congestion. P Patient factors atient factors Glycopyrronium bromide tablets and oral solution or suspension are imported or prepared by 'specials' manufacturers. Dosage varies: generally given 3 times daily, titrated and dependent on weight in children (Cuvposa labelling advises to give either 1 hour before, or 2 hours after, meals). Oral

2013 National Institute for Health and Clinical Excellence - Advice

200. Anticoagulation - oral

Anticoagulation - oral Anticoagulation - oral - NICE CKS Share Anticoagulation - oral: Summary There are five oral anticoagulants licensed for use in the UK: warfarin, apixaban, dabigatran, edoxaban and rivaroxaban. Apixaban, dabigatran, edoxaban and rivaroxaban are newer anticoagulants which may be prescribed instead of warfarin for people with non-valvular atrial fibrillation (NVAF): Apixaban, dabigatran, edoxaban and rivaroxaban have been approved by the National Institute for Health (...) in secondary care consists of stopping treatment and general haemostatic measures, such as mechanical compression and surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy), or platelets. People taking oral anticoagulants should be advised: To seek immediate medical advice if spontaneous bleeding occurs and does not stop, or recurs. This includes bruising

2019 NICE Clinical Knowledge Summaries

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>